<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823442</url>
  </required_header>
  <id_info>
    <org_study_id>2021-3791</org_study_id>
    <nct_id>NCT04823442</nct_id>
  </id_info>
  <brief_title>Activation of Brown Adipose Tissue Metabolism Using Mirabegron</brief_title>
  <acronym>GB9</acronym>
  <official_title>Sympathomimetics and Sympatholytics in Type 2 Diabetes: Teaching Old Drugs New Tricks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Could sympathomimetics and sympatholytics drugs safe for the management of Type 2 Diabetes&#xD;
      (T2D)? Based on recent evidence, we propose that pharmacological stimulation of Beta-3&#xD;
      adrenergic receptor (ADBR3) at higher doses of Mirabegron may be required to elicit changes&#xD;
      in glycemia, but should be combined with Beta-1 adrenergic receptor (ADRB1) antagonists to&#xD;
      suppress the unwanted effects on the cardiovascular system.&#xD;
&#xD;
      Together, several results establish a previously unappreciated cross-talk between Gs-coupled&#xD;
      ADRB1 and ADRB3 in adipose tissue for the control of glucose homeostasis. Moreover, these&#xD;
      data suggest that antagonizing ADRB1 may be a good way to significantly lower the dose of&#xD;
      ADRB3 agonist required for glucose control.&#xD;
&#xD;
      Therefore, we believe that there are therapeutic opportunities in targeting adrenergic&#xD;
      receptors for the treatment of T2D at least in young/middle aged people.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In brief, participants will take part in 2 metabolic studies (A and B) performed in random&#xD;
      order and at an interval of 7 to 14 days. Each metabolic study will last 8.5 hours with a&#xD;
      baseline period of 2.5 hours. Participants will ingest either 200 mg of the ADRB3 agonist&#xD;
      mirabegron (Myrbetriq, Astellas Pharma Canada) alone (study A) or in combination with 10 mg&#xD;
      of bisoprolol, an ADRB1-antagonist (study B), at time 0.&#xD;
&#xD;
      The radioactive PET tracers (PET: positron emission tomography) used in this study are the&#xD;
      [11C]-acetate and [18F]-FDG to estimate BAT oxidative metabolism and glucose metabolism,&#xD;
      respectively. The perfusion of [6,6 D2]-glucose, [1,1,2,3,3-2H]-glycerol and&#xD;
      [U-13C]-palmitate stable isotopes will also be performed in this study from time -150 min. to&#xD;
      +300 min to examine the systemic appearance rate of glucose, glycerol and fatty acids,&#xD;
      respectively. These studies will be almost identical (same perfusion of stable and&#xD;
      radioactive tracers, same number of PET acquisitions) except for the drug which will be&#xD;
      administered orally at time 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow)</measure>
    <time_frame>30 minutes before and 210 minutes after drug administration</time_frame>
    <description>Measured with 11C-acetate using dynamic PET/CT acquisition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT glucose uptake</measure>
    <time_frame>240 minutes after drug administration</time_frame>
    <description>Assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole-body glucose partitioning</measure>
    <time_frame>300 minutes after drug administration</time_frame>
    <description>Assessed using i.v. injection of 18FDG with static PET/CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body lipolysis</measure>
    <time_frame>150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).</time_frame>
    <description>Systemic appearance rate of glycerol and fatty acid determined by perfusion of [1,1,2,3,3-2H]-glycerol, [U-13C]-palmitate tracers. and concentration of total NEFA, triglycerides, palmitate, oleate, linoleate, glycerol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Glucose production</measure>
    <time_frame>150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).</time_frame>
    <description>Systemic appearance rate of glucose determined by perfusion of [6,6 D2]-glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substrate utilisation</measure>
    <time_frame>150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state).</time_frame>
    <description>VO2 and VCO2 will be measured by indirect calorimetry to calculate carbohydrate and fatty acid oxidation rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT lipolysis</measure>
    <time_frame>baseline and 300 minutes after drug administration</time_frame>
    <description>Estimated by quantifying changes in tissue radiodensity with CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pancreatic and gut hormones</measure>
    <time_frame>150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).</time_frame>
    <description>measured with ELISA and Milliplex.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Study A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metabolic PET study with mirabegron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metabolic PET study with mirabegron and bisoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)</description>
    <arm_group_label>Study A</arm_group_label>
    <arm_group_label>Study B</arm_group_label>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol Fumarate</intervention_name>
    <description>a single dose of 10 mg (2 tablets of 5 mg)</description>
    <arm_group_label>Study B</arm_group_label>
    <other_name>Apo Bisoprolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects with normal glucose tolerance determined according to an oral glucose&#xD;
             tolerance test;&#xD;
&#xD;
          -  BMI ≤ 30 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plasma triglycerides &gt; 5.0 mmol/L at fasting;&#xD;
&#xD;
          -  More than 2 alcohol consumption per day;&#xD;
&#xD;
          -  More than 1 cigarette per day;&#xD;
&#xD;
          -  History of total cholesterol level &gt; 7 mmol/L, of cardiovascular disease, hypertensive&#xD;
             crisis;&#xD;
&#xD;
          -  Treatment with fibrates, thiazolidinedione, insulin,betablockers or other drugs with&#xD;
             effects on insulin resistance or lipid metabolism (exception for antihypertensive&#xD;
             drugs, statins or metformin);&#xD;
&#xD;
          -  Presence of a noncontrolled thyroid disease, renal or hepatic disease, history of&#xD;
             pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical&#xD;
             conditions;&#xD;
&#xD;
          -  History of serious gastrointestinal disorders (malabsorption, peptic ulcer,&#xD;
             gastroesophageal reflux having required a surgery, etc.); reflux having required a&#xD;
             surgery, etc.);&#xD;
&#xD;
          -  Presence of a pacemaker;&#xD;
&#xD;
          -  Have undergone of PET study or CT scan in the past year;&#xD;
&#xD;
          -  Chronic administration of any medication;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Blondin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Frisch</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12394</phone_ext>
    <email>frederique.frisch@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Frisch</last_name>
      <phone>819-346-1110</phone>
      <email>frederique.frisch@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Denis Blondin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Carpentier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Éric Turcotte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Denis Blondin</investigator_full_name>
    <investigator_title>Assisant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

